Form 8-K - Current report:
SEC Accession No. 0001558370-24-013518
Filing Date
2024-10-23
Accepted
2024-10-23 16:11:13
Documents
14
Period of Report
2024-10-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crvs-20241022x8k.htm   iXBRL 8-K 43235
2 EX-10.1 crvs-20241022xex10d1.htm EX-10.1 217467
  Complete submission text file 0001558370-24-013518.txt   422006

Data Files

Seq Description Document Type Size
3 EX-101.SCH crvs-20241022.xsd EX-101.SCH 3282
4 EX-101.LAB crvs-20241022_lab.xml EX-101.LAB 15268
5 EX-101.PRE crvs-20241022_pre.xml EX-101.PRE 9937
16 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20241022x8k_htm.xml XML 4738
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 241389327
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)